<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03101514</url>
  </required_header>
  <id_info>
    <org_study_id>201708</org_study_id>
    <nct_id>NCT03101514</nct_id>
  </id_info>
  <brief_title>Kanglaite Reduce the Toxicity of Radiotherapy of Head and Neck Cancer Phase II Study</brief_title>
  <official_title>First Affiliated Hospital of Harbin Medical University</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Harbin Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      About 89%-100% patients with head and neck malignant tumors have radiation mucositis during
      their radiotherapy. Until now, there is no effective method to prevent mucositis. Steroid
      hormone, pain-relief, anti-inflammatory and other symptom-relief treatments usually are used
      after the emergence of mucositis. Coixenol triglyceride is an ester extract of Coix Seed. Its
      trade name is Kanglaite Injection, which has been approved in China and Russia. Kanglaite has
      anti-tumor effect and reduce treatment toxicity of tumor. Kanglaite could also improve the
      quality of life of patients and mitigate the condition of the cachexia. In china, two studies
      evaluating treatment of Kanglaite to nasopharyngeal cancer, found that Kanglaite can reduce
      radiotherapy mucositis. So far, Kanglaite on the prevention and treatment of radiation
      mucositis of the head and neck malignant tumor is still lack of strong clinical trial
      evidence. This is a phase II, single center, one arm study with subject to evaluate the acute
      radiation mucositis, nutritional status, and quality of life on the course of radiotherapy of
      head and neck cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      3-4 grade radiation mucositis account for 34%-56% in all head and neck patients treated by
      radiotherapy and &gt;50% in patients treated by radiotherapy concurrent with chemotherapy. 3-4
      grade radiation mucositis have obvious symptoms, presenting with fusion ulcers, ulcers
      bleeding or obvious pain need analgesic drugs. At this time, the patients can not eat or can
      only intake fluid diet, which led to weight loss, malnutrition, quality of life declined and
      a series of problems.

      Kanglaite has anti-tumor effect and reduce treatment toxicity of tumor. Kanglaite can reduce
      radiotherapy mucositis of nasopharyngeal cancer had been found initially in Chinese.
      Kanglaite on the prevention and treatment of radiation mucositis of the head and neck
      malignant tumor is still lack of strong clinical trial evidence. This is a phase II, single
      center, one arm study with subject to evaluation the acute radiation mucositis, nutritional
      status, and quality of life on the course of radiotherapy of head and neck malignant tumors.

      Kanglaite 200ml is injected intravenous from the first day to the last day of radiotherapy.
      Chemotherapy with cisplatin or nedaplatin (both 80-100mg/m2, 21 day per cycle, 1-3 cycles) is
      used or not concurrent with radiotherapy. There is no order of Kanglaite injection and
      radiotherapy. Granulocyte colony stimulating factor and antibiotics have no prophylactic use,
      but can be used after the decline of white blood cells. Mucositis, nutritional status, and
      quality of life are evaluated before radiotherapy, every week of radiotherapy, 4 weeks after
      radiotherapy. Mucositis is verified by physical examination. Nutritional status is evaluated
      by patient-generated subjective global assessment (PG-SGA) scale. Quality of life is
      evaluated by EORTC QLQ-C30 and QLQ-H&amp;N35 questionnaire.

      This is a one arm study, sample size calculation based on the incidence of 3-4 degree
      mucositis. The incidence of 3-4 degree mucositis is about &gt;50% according to literatures of
      head and neck squamous cell carcinoma intensity modulated radiation therapy concurrent with
      chemotherapy. So we assume that Kanglaite can reduce 3-4 degree mucositis from 50% to 30%.
      The sample size required 44 cases according to the superiority test, bilateral Class I error
      α = 0.05, class II error β = 0.2. Total 49 cases are need, assuming the off rate of 10%.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Kanglaite injection + Radiotherapy ± Chemotherapy</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the incidence rate of radiation mucositis</measure>
    <time_frame>From date of randomization until the date of 4-8 weeks after radiotherapy,assessed up to 4 months</time_frame>
    <description>the incidence rate of radiation mucositis assessed by CTCAE v4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the incidence rate of non-hematologic toxicity side events</measure>
    <time_frame>From date of randomization until the date of 4-8 weeks after radiotherapy,assessed up to 4 months</time_frame>
    <description>the incidence rate of non-hematologic toxicity side events assessed by CTCAE v4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the incidence rate of hematologic toxicity side events</measure>
    <time_frame>From date of randomization until the date of 4-8 weeks after radiotherapy,assessed up to 4 months</time_frame>
    <description>the incidence rate of hematologic toxicity side events assessed by CTCAE v4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the nutritional status</measure>
    <time_frame>From date of randomization until the date of 4-8 weeks after radiotherapy,assessed up to 4 months</time_frame>
    <description>the nutritional status scored by patient-generated subjective global assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the overall quality of life</measure>
    <time_frame>From date of randomization until the date of 4-8 weeks after radiotherapy,assessed up to 4 months</time_frame>
    <description>the quality of life scored by EORTC QLQ-C30 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the quality of life specific on head and neck</measure>
    <time_frame>From date of randomization until the date of 4-8 weeks after radiotherapy,assessed up to 4 months</time_frame>
    <description>the quality of life scored by EORTC QLQ-H&amp;N35 questionnaire</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">49</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Radiotherapy</condition>
  <arm_group>
    <arm_group_label>Kanglaite group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Kanglaite 200ml is injected once a day from Monday to Friday during radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kanglaite</intervention_name>
    <description>Kanglaite injection 200ml is injected intravenous from the first day to the last day of radiotherapy.</description>
    <arm_group_label>Kanglaite group</arm_group_label>
    <other_name>Kanglaite injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18-80 years old, expected survival period ≥ 12 months

          2. Karnofsky score ≥80 points

          3. Pathological confirmed head and neck malignant tumors (oral, oropharynx, hypopharynx,
             throat, nasopharynx, nasal paranasal sinus or other), radical radiotherapy (±
             chemotherapy) or postoperative radiotherapy (± chemotherapy), radiotherapy dose 60
             -70Gy

          4. with or without induction chemotherapy (induced chemotherapy ≤ 3 cycles);

          5. Meet the following laboratory diagnostic indicators:

             Hemoglobin ≥120g / L, white blood cells 4.0-10.0 × 109 / L, neutrophils 2.0-7.5 × 109
             / L, platelets 100-300 × 109 / L; creatinine ≤ normal upper limit (UNL); ALT and AST ≤
             2.5 × UNL, alkaline phosphatase (ALP) ≤ 5 × UNL, total bilirubin (Tbil) ≤ UNL

          6. Sign informed consent.

        Exclusion Criteria:

          1. Distant metastases

          2. Allergy to Kanglaite

          3. Head and neck had previously received radiation therapy

          4. Pregnancy or lactation patients

          5. Targeted drug therapy during radiotherapy

          6. Radio-chemotherapy uses cytotoxic drugs other than platinum

          7. Currently active infections, or combined with rheumatic immune diseases, long-term
             chronic infection, acute infection, inflammatory state; hematopoietic dysfunction of
             the blood system diseases; severe cardiopulmonary disease

          8. Mental history, can not cooperate with the treatment

          9. Researchers believe unsuitable to participate in this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhi-Ping Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Harbin Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhi-Ping Liu, MD</last_name>
    <phone>+8613936034546</phone>
    <email>as150001@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liu</last_name>
    <phone>+86045185552350</phone>
    <email>kykbgs123@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liu</last_name>
      <phone>+86045185552350</phone>
      <email>kykbgs123@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhao</last_name>
      <phone>+86045185552350</phone>
      <email>kykbgs123@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>ZhinPing Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jie Chen, MM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Si-Han Liu, MM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cheng-Ling Chu, MM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yu-Xin Ren, MM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.cnki.net/KCMS/detail/detail.aspx?QueryID=1&amp;CurRec=1&amp;filename=YWLC201311028&amp;dbname=CJFD2013&amp;dbcode=CJFQ&amp;pr=&amp;urlid=&amp;yx=&amp;uid=WEEvREcwSlJHSldRa1FhdkJkcGkzcVBMVDlLcXRDRGlQd3hhNzRBZkFjbz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!&amp;v=MTgzNDJDVVJMMmZaT1J2Rml6Z1ViN0FQRHJIYmJHNEg5TE5ybzlIYklSOGVYMUx1eFlTN0RoMVQzcVRyV00xRnI=</url>
    <description>Jing JL, Li XL, Nan YQ. Advances in the study of the effect of Kanglaite injection on tumor therapy. Chinese Remedies &amp; Clinics, 2013;13(11):1447-1448 (in Chinese).</description>
  </link>
  <link>
    <url>http://www.cnki.net/KCMS/detail/detail.aspx?QueryID=6&amp;CurRec=1&amp;filename=XDYD199806032&amp;dbname=CJFD9899&amp;dbcode=CJFQ&amp;pr=&amp;urlid=&amp;yx=&amp;uid=WEEvREcwSlJHSldRa1FhdkJkcGkzcVBMVDlLcXRDRGlQd3hhNzRBZkFjbz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!&amp;v=MjczNDlPUnZGaXpnVkx6QVBTblNhckt4RjluTXFZOUdab1I4ZVgxTHV4WVM3RGgxVDNxVHJXTTFGckNVUkwyZlo=</url>
    <description>Guo Y, Li DP. Protective effects of Kanglaite injection on hematopoiesis and liver and kidney damage caused by three anticancer drugs. Chinese journal of modern applied phaemacy.1998;15(6):61-62(in Chinese).</description>
  </link>
  <link>
    <url>http://www.cnki.net/KCMS/detail/detail.aspx?QueryID=0&amp;CurRec=1&amp;filename=QLZL200306029&amp;dbname=CJFD2003&amp;dbcode=CJFQ&amp;pr=&amp;urlid=&amp;yx=&amp;uid=WEEvREcwSlJHSldRa1FhdkJkcGkzcVBMVDlLcXRDRGlQd3hhNzRBZkFjbz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!&amp;v=MDkyNDc0SHRMTXFZOUhiWVI4ZVgxTHV4WVM3RGgxVDNxVHJXTTFGckNVUkwyZlpPUnZGaS9rVnIvSk5DSFJZckc=</url>
    <description>Wang WD, Sun SP, Wang XD. Influence of KLT on Radiotherapy Effect of Patients with Advanced Nasopharyngeal Carcinoma. China Journal of Cancer Prevention and Treatment,2003:10(6): 635-637(in Chinese).</description>
  </link>
  <link>
    <url>http://www.cnki.net/KCMS/detail/detail.aspx?QueryID=0&amp;CurRec=1&amp;filename=XYJH200506008&amp;dbname=CJFD2005&amp;dbcode=CJFQ&amp;pr=&amp;urlid=&amp;yx=&amp;uid=WEEvREcwSlJHSldRa1FhdkJkcGkzcVBMVDlLcXRDRGlQd3hhNzRBZkFjbz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!&amp;v=MDM5ODBlWDFMdXhZUzdEaDFUM3FUcldNMUZyQ1VSTDJmWk9SdkZpL2xWYnZBUFRUQlpyRzRIdFRNcVk5RmJJUjg=</url>
    <description>Ren ZP, et al. The therapeutic effects of the combined therapy with kanglaite injection and radiotherapy on nasopharyngea carcinoma among aged cases. Chinese Journal of Otorhinolaryngology of Integrated Traditional and Western Medici 2005;13(6)</description>
  </link>
  <results_reference>
    <citation>Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK, Komaroff E, Nalysnyk L, Zilberberg MD. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol. 2003 Mar;66(3):253-62. Review.</citation>
    <PMID>12742264</PMID>
  </results_reference>
  <results_reference>
    <citation>Redding SW. Cancer therapy-related oral mucositis. J Dent Educ. 2005 Aug;69(8):919-29.</citation>
    <PMID>16081575</PMID>
  </results_reference>
  <results_reference>
    <citation>Silverman S Jr. Diagnosis and management of oral mucositis. J Support Oncol. 2007 Feb;5(2 Suppl 1):13-21. Review.</citation>
    <PMID>17366929</PMID>
  </results_reference>
  <results_reference>
    <citation>Harris DJ. Cancer treatment-induced mucositis pain: strategies for assessment and management. Ther Clin Risk Manag. 2006 Sep;2(3):251-8.</citation>
    <PMID>18360600</PMID>
  </results_reference>
  <results_reference>
    <citation>Rodríguez-Caballero A, Torres-Lagares D, Robles-García M, Pachón-Ibáñez J, González-Padilla D, Gutiérrez-Pérez JL. Cancer treatment-induced oral mucositis: a critical review. Int J Oral Maxillofac Surg. 2012 Feb;41(2):225-38. doi: 10.1016/j.ijom.2011.10.011. Epub 2011 Nov 8. Review.</citation>
    <PMID>22071451</PMID>
  </results_reference>
  <results_reference>
    <citation>Walsh L, Gillham C, Dunne M, Fraser I, Hollywood D, Armstrong J, Thirion P. Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC). Radiother Oncol. 2011 Jan;98(1):38-41. doi: 10.1016/j.radonc.2010.11.009. Epub 2010 Dec 13.</citation>
    <PMID>21159400</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen Y, Liu MZ, Liang SB, Zong JF, Mao YP, Tang LL, Guo Y, Lin AH, Zeng XF, Ma J. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china. Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1356-64. doi: 10.1016/j.ijrobp.2007.12.028. Epub 2008 May 9.</citation>
    <PMID>18472356</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2017</study_first_submitted>
  <study_first_submitted_qc>March 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2017</study_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>head and neck</keyword>
  <keyword>tumor</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>mucositis</keyword>
  <keyword>toxicity</keyword>
  <keyword>Kanglaite injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The investigators have no other clinical trial about cancer of head and neck</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

